Category Press Releases

Avanzanite Bioscience Appoints Dr. Mark Bechter as Senior Vice President of Medical Affairs

Avanzanite Bioscience Strengthens Leadership with Appointment of Dr. Mark Bechter as Senior Vice President of Medical Affairs Avanzanite Bioscience B.V., a rapidly expanding European specialty pharmaceutical company dedicated to improving the lives of patients with rare diseases, announced today the…

Read MoreAvanzanite Bioscience Appoints Dr. Mark Bechter as Senior Vice President of Medical Affairs
Nuvig Therapeutics

Nuvig Therapeutics Names David Woodhouse CEO, James Mackay Board Chair

Nuvig Therapeutics Strengthens Leadership Team with Appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company dedicated to developing transformative immunomodulatory therapeutics for…

Read MoreNuvig Therapeutics Names David Woodhouse CEO, James Mackay Board Chair
Alnylam

Alnylam to Launch $500 Million Convertible Senior Notes Offering

Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader in RNA interference (RNAi) therapeutics, has announced the commencement of…

Read MoreAlnylam to Launch $500 Million Convertible Senior Notes Offering

Aptar Pharma, Dianosic Partner on Intranasal Scaffold for Allergy & Sinus Care

Aptar Pharma and Dianosic Forge Exclusive Partnership to Advance Resorbable Intranasal Scaffold Technology for Chronic Rhinitis, Sinusitis, and Beyond In a strategic move that underscores the growing importance of patient-centric intranasal drug delivery platforms, Aptar Pharma, a global leader in…

Read MoreAptar Pharma, Dianosic Partner on Intranasal Scaffold for Allergy & Sinus Care

MRM Health Secures €55M Series B for Microbiome Therapeutics

MRM Health Secures €55 Million Series B Financing to Accelerate Development of Best-in-Class Microbiome-Based Biotherapeutics MRM Health NV, a pioneering clinical-stage biopharmaceutical company developing transformative microbiome-based therapeutics, announced the successful closing of a €55 million (approximately US$64 million) Series B…

Read MoreMRM Health Secures €55M Series B for Microbiome Therapeutics

MEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479

MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…

Read MoreMEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479

Neurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors

Neurotech Pharmaceuticals Strengthens Leadership with Appointment of Dr. Peter J. McDonnell to Board of Directors Neurotech Pharmaceuticals, Inc., a privately held biotechnology company pioneering transformative therapies for chronic eye diseases, today announced the appointment of Peter J. McDonnell, M.D., a…

Read MoreNeurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors

Enlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers

Enlaza Therapeutics and Vertex Pharmaceuticals Forge Multi-Billion-Dollar Collaboration to Advance Next-Generation Covalent Biologics in Autoimmune Diseases and Conditioning Therapies Enlaza Therapeutics (“Enlaza” or the “Company”), a pioneering biotechnology firm and the first company to build a dedicated covalent biologics platform,…

Read MoreEnlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers